摘要
目的观察比较诺和锐30和诺和灵30R治疗肝源性糖尿病的临床疗效。方法将48例肝源性糖尿病患者随机分成诺和锐30组和诺和灵30R组，治疗12周后，观察两种不同治疗方案患者空腹血糖（FBG）、餐后2h血糖（2hPBG）、糖化血红蛋白（HbAlc）、胰岛素剂量变化及低血糖发生的情况。结果①两组治疗后FBG、2hPBG、HbAIc均明显下降（P〈0．01），但诺和锐30组餐后血糖、糖化血红蛋白下降更明显（P〈0．01）；②诺和锐30组低血糖发生率明显低于诺和灵30R组（P〈0．05）；③诺和锐30组胰岛素剂量增加幅度高于诺和灵30R组，但差异无统计学意义（P〉0．05）。结论诺和锐30能更好地降低肝源性糖尿病患者的血糖水平，尤其是餐后血糖，且不增加低血糖的风险。
Objective To evaluate the effect of insulin aspart 30 injection and novolin 30R profile in treament of hepatogenic diabetes. Methods Forty-eight patients with hepatogenic diabetes were randomly divided into two groups： insulin aspart 30 injection group and novolin 30R profile group. After 12 weeks, the levels of fasting plasma glucose （FBG）, 2 hours postprandial glucose （2 hPBG）, glycosylated hemoglobin A1 c （ HbA1 c）, insulin dosages, frequency of hypoglycemia were compared before and after the treament. Results ①FBG,2 hPBG, HbA1 c were significantly decreased in two groups （P〈0.01） , but insulin aspart 30 injection group was associated with a significantly lower 2 hPBG, HbAlc than novolin 30R profill group （P〈0.01）. ②The frequency of hypoglycemia of insulin aspart 30 injection group was significantly lower than that of novolin 30R profile group （P〈0.05）.③The level of insulin dosages of insulin aspart 30 injection groups was higher than that of novolin 30R profile groups （P〉0.05）. Conclusion Insulin aspart 30 injection can effectively decrease 2 hour postprandial glucose and frequency of hypoglycemia in hepatogenic diabetes.
出处
《中国实用医刊》
2008年第21期18-20,共3页
Chinese Journal of Practical Medicine
关键词
诺和锐
诺和灵
临床研究
有效性
糖尿病
肝源性
Insulin aspart
Novolin
Clinical trial
Efficacy
Hepatogenic diabetes
